Guardant Health ( GH) leads the pack with an impressive YTD performance of +226.48%, earning a Strong Buy Quant Rating.

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Guardant Health, Inc. is one ...

Canaccord raised the firm’s price target on Guardant Health (GH) to $125 from $100 and keeps a Buy rating on the shares. The firm previewed its ...

Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-positive, HER2-negative breast cancer for treatment with imlunes ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with Epic, the nation’s most widely used comprehensive ...

PALO ALTO, Calif., November 04, 2025--(BUSINESS WIRE)--Guardant Health, Inc. ("Guardant Health") (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $300.0 ...

PALO ALTO, Calif., November 05, 2025--(BUSINESS WIRE)--Guardant Health, Inc. ("Guardant Health") (Nasdaq: GH), a leading precision oncology company, today announced the pricing of its upsized offering ...

In the last three months, 7 analysts have published ratings on Guardant Health (NASDAQ:GH), offering a diverse range of perspectives from bullish to bearish. The following table provides a quick ...

Reported total revenue of $232.1 million, an increase of 31%, driven by: Oncology revenue of $158.7 million, an increase of 22%, and approximately 64,000 oncology tests, an increase of 30% Screening ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, ...

I was a little late to the party in buying Guardant Health (GH-3.35%). After watching the stock soar during the latter part of 2018 and the first half of 2019, I finally jumped in to scoop up shares ...

Craig-Hallum used to like Exact Sciences stock -- but now it likes Guardant Health even more. Five years from now, the investment banker thinks Guardant's annual revenue could be three times what it ...